These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 3226597)

  • 1. [Adjuvant therapy in breast carcinoma. A specific immunologic preliminary contribution].
    Fazio M; Calabrese F; Giacomasso S; Mastromatteo V; Negri L
    Minerva Chir; 1988 Sep; 43(18 Suppl):59-62. PubMed ID: 3226597
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant chemotherapy of early breast cancer.
    Med Lett Drugs Ther; 1990 May; 32(818):49-50. PubMed ID: 2333039
    [No Abstract]   [Full Text] [Related]  

  • 3. [Neo-adjuvant chemotherapy].
    Bumma C; Perroni D; Grecchi GL; Lauria G; Pautasso M
    Minerva Chir; 1988 Sep; 43(18 Suppl):55-8. PubMed ID: 3067122
    [No Abstract]   [Full Text] [Related]  

  • 4. [Adjuvant chemo-hormonal therapy of breast cancer. New results on mortality].
    Kaufmann M; Kubli F; Caffier H; Jonat W; Maass H
    Dtsch Med Wochenschr; 1985 Jun; 110(25):1009-10. PubMed ID: 3839181
    [No Abstract]   [Full Text] [Related]  

  • 5. [Adjuvant therapy of breast carcinoma].
    Kaufmann M
    Dtsch Med Wochenschr; 1994 Mar; 119(11):387-91. PubMed ID: 8131718
    [No Abstract]   [Full Text] [Related]  

  • 6. [Adjuvant therapy of breast cancer].
    Semiglazov VF; Abzumanov AS; Bozhok AA; Ivanov VG; Ivanova OA; Barash NIu; Topuzov EE; Seleznev IK; Migmanova NSh; Popova RT; Nurgaziev KSh
    Khirurgiia (Mosk); 2001; (5):52-60. PubMed ID: 11505673
    [No Abstract]   [Full Text] [Related]  

  • 7. National Institutes of Health Consensus Development Conference on Adjuvant Chemotherapy and Endocrine Therapy for Breast Cancer. Editorial overview.
    Lippman ME; Chabner BA
    NCI Monogr; 1986; (1):5-10. PubMed ID: 3534591
    [No Abstract]   [Full Text] [Related]  

  • 8. Expression of bcl-2 protein predicts efficacy of adjuvant treatments in operable node-positive breast cancer.
    Gasparini G; Barbareschi M; Doglioni C; Palma PD; Mauri FA; Boracchi P; Bevilacqua P; Caffo O; Morelli L; Verderio P
    Clin Cancer Res; 1995 Feb; 1(2):189-98. PubMed ID: 9815973
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Adjuvant therapy in breast cancer].
    Semiglazov VF
    Vopr Onkol; 2000; 46(1):18-27. PubMed ID: 10789218
    [No Abstract]   [Full Text] [Related]  

  • 10. [Medical treatment of breast carcinoma].
    Rosso R; Gardin G
    Ann Ital Chir; 1991; 62(5):467-77. PubMed ID: 1801625
    [No Abstract]   [Full Text] [Related]  

  • 11. [Adjuvant therapies in breast carcinoma].
    Joss R; Brunner K
    Schweiz Rundsch Med Prax; 1991 Mar; 80(11):247-54. PubMed ID: 2024099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant treatment of breast cancer.
    Akerley WL
    R I Med; 1995 Sep; 78(9):250-3. PubMed ID: 7579720
    [No Abstract]   [Full Text] [Related]  

  • 13. A prognostic table to guide practitioners advising patients on adjuvant systemic therapy in early breast cancer.
    Stotter A
    Eur J Surg Oncol; 1999 Aug; 25(4):341-3. PubMed ID: 10419700
    [No Abstract]   [Full Text] [Related]  

  • 14. Clinical relevance of vascular endothelial growth factor and thymidine phosphorylase in patients with node-positive breast cancer treated with either adjuvant chemotherapy or hormone therapy.
    Gasparini G; Toi M; Miceli R; Vermeulen PB; Dittadi R; Biganzoli E; Morabito A; Fanelli M; Gatti C; Suzuki H; Tominaga T; Dirix LY; Gion M
    Cancer J Sci Am; 1999; 5(2):101-11. PubMed ID: 10198732
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adjuvant systemic therapy in primary breast cancer.
    Mouridsen HT; Palshof T
    Acta Chir Scand Suppl; 1984; 519():43-53. PubMed ID: 6393664
    [No Abstract]   [Full Text] [Related]  

  • 16. Postoperative adjuvant chemotherapy followed by adjuvant tamoxifen versus nil for patients with operable breast cancer: a randomised phase III trial of the European Organisation for Research and Treatment of Cancer Breast Group.
    Morales L; Canney P; Dyczka J; Rutgers E; Coleman R; Cufer T; Welnicka-Jaskiewicz M; Nortier J; Bogaerts J; Therasse P; Paridaens R; ;
    Eur J Cancer; 2007 Jan; 43(2):331-40. PubMed ID: 17134892
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Poor outcome of hormone receptor-positive breast cancer at very young age is due to tamoxifen resistance: nationwide survival data in Korea--a report from the Korean Breast Cancer Society.
    Ahn SH; Son BH; Kim SW; Kim SI; Jeong J; Ko SS; Han W;
    J Clin Oncol; 2007 Jun; 25(17):2360-8. PubMed ID: 17515570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Systemic adjuvant therapy for breast cancer.
    Reed EC
    Nebr Med J; 1996 Mar; 81(3):48-50. PubMed ID: 8907820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor angiogenesis predicts clinical outcome of node-positive breast cancer patients treated with adjuvant hormone therapy or chemotherapy.
    Gasparini G; Barbareschi M; Boracchi P; Verderio P; Caffo O; Meli S; Dalla Palma P; Marubini E; Bevilacqua P
    Cancer J Sci Am; 1995; 1(2):131-41. PubMed ID: 9166466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [General evaluation of adjuvant chemotherapy trials in breast cancer (excluding the Milan trial)].
    Gest J
    Bull Cancer; 1984; 71(4):336-44. PubMed ID: 6388672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.